Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

First CGM System With Implantable Glucose Sensor Approved

First CGM System With Implantable Glucose Sensor Approved

By

The sensor is coated with a fluorescent chemical which produces a small amount of light when exposed to blood glucose.

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

By

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

CVS Pharmacy Launches Prescription Delivery Service Nationwide

CVS Pharmacy Launches Prescription Delivery Service Nationwide

By

CVS Pharmacy is now offering home delivery nationwide for prescription drugs, for a service charge of $4.99.

Hypoparathyroidism Treatment Granted Orphan Drug Designation

Hypoparathyroidism Treatment Granted Orphan Drug Designation

By

TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore PTH to physiologic levels, normalizing blood and urinary calcium levels, serum phosphate levels and bone turnover.

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

By

For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.

More Articles by Steve Duffy

Sign Up for Free e-Newsletters



CME Focus